HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
KDSR
3-ketodihydrosphingosine reductase
Chromosome 18 Β· 18q21.33
NCBI Gene: 2531Ensembl: ENSG00000119537.19HGNC: HGNC:4021UniProt: Q06136
50PubMed Papers
21Diseases
0Drugs
7Pathogenic Variants
FUNCTIONAL ROLE
Oncogene
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
3-keto-sphinganine metabolic processprotein binding3-dehydrosphinganine reductase activitysphingolipid biosynthetic processerythrokeratodermia variabilis et progressiva 4erythrokeratodermia variabilisprostate carcinomablood platelet disease
✦AI Summary

KDSR (3-ketodihydrosphingosine reductase) is a critical endoplasmic reticulum enzyme that catalyzes the reduction of 3-ketodihydrosphingosine to sphinganine, the second step of de novo sphingolipid biosynthesis 1. This enzymatic function is essential for producing ceramides and other sphingolipids required for membrane trafficking, cell differentiation, and protein homeostasis 2. Loss-of-function KDSR mutations disrupt cellular ceramide synthesis and trigger compensatory activation of the sphingolipid salvage pathway, leading to accumulation of sphingosine and sphingosine 1-phosphate 1. This metabolic dysregulation causes ER stress, oxidative stress, and mitochondrial dysfunction 12. Biallelic KDSR mutations cause erythrokeratodermia variabilis et progressiva-4 (EKVP-4), characterized by hyperkeratotic plaques and progressive erythema 3. The disorder manifests as a spectrum of keratinization disorders ranging from palmoplantar keratoderma to generalized ichthyosis, frequently accompanied by thrombocytopenia due to impaired proplatelet formation in megakaryocytes 45. Additional manifestations include hepatic injury, steatosis, and megakaryocyte dysplasia 16. KDSR dysfunction also holds therapeutic potential in leukemia, where KDSR suppression combined with ER-stress induction shows synergistic effects 2.

Sources cited
1
KDSR is the key enzyme in de novo sphingolipid synthesis; loss-of-function mutations cause hepatomegaly progressing to steatosis and hepatic injury through S1P accumulation and ER/oxidative stress
PMID: 30718751
2
KDSR is essential for leukemia cell maintenance through regulation of ER homeostasis and unfolded protein response; KDSR depletion causes KDS accumulation and UPR dysfunction
PMID: 34373586
3
KDSR mutations are associated with erythrokeratodermia variabilis et progressiva (EKVP), a rare hereditary skin disorder with progressive hyperkeratotic and erythematous manifestations
PMID: 39513663
4
Biallelic KDSR mutations cause reduced ceramide levels and impaired platelet function; mutations result in spectrum of keratinization disorders with thrombocytopenia as consistent feature
PMID: 28774589
5
KDSR deficiency impairs proplatelet formation and megakaryocyte differentiation, causing thrombocytopenia; sphingolipids regulate cytoskeletal organization during megakaryopoiesis
PMID: 30467204
6
KDSR mutations in skin keratinocytes lead to formation of unusual keto-type ceramides and shorter sphingoid base chain lengths due to metabolic flux bottleneck
PMID: 34686882
7
Homozygotic KDSR mutations associate with severe thrombocytopenia, keratinization disorders, and hepatic hemangioendothelioma
PMID: 32972506
Disease Associationsβ“˜21
erythrokeratodermia variabilis et progressiva 4Open Targets
0.78Strong
erythrokeratodermia variabilisOpen Targets
0.46Moderate
prostate carcinomaOpen Targets
0.42Moderate
blood platelet diseaseOpen Targets
0.37Weak
neurodegenerative diseaseOpen Targets
0.36Weak
lymphoid neoplasmOpen Targets
0.19Weak
chronic lymphocytic leukemiaOpen Targets
0.19Weak
genetic disorderOpen Targets
0.19Weak
multiple myelomaOpen Targets
0.19Weak
pancreatic ductal adenocarcinomaOpen Targets
0.19Weak
brain glioblastomaOpen Targets
0.18Weak
breast ductal adenocarcinomaOpen Targets
0.18Weak
carcinoma of liver and intrahepatic biliary tractOpen Targets
0.18Weak
clear cell renal carcinomaOpen Targets
0.18Weak
Endometrial Endometrioid AdenocarcinomaOpen Targets
0.18Weak
esophageal adenocarcinomaOpen Targets
0.18Weak
gastric adenocarcinomaOpen Targets
0.18Weak
HER2 Positive Breast CarcinomaOpen Targets
0.18Weak
lung adenocarcinomaOpen Targets
0.18Weak
non-small cell lung carcinomaOpen Targets
0.18Weak
Erythrokeratodermia variabilis et progressiva 4UniProt
Pathogenic Variants7
NM_002035.4(KDSR):c.879G>A (p.Gln293=)Likely pathogenic
Erythrokeratodermia variabilis et progressiva 4|not provided|Clear cell carcinoma of kidney|Acute myeloid leukemia|Sarcoma
β˜…β˜…β˜†β˜†2025β†’ Residue 293
NM_002035.4(KDSR):c.190C>T (p.Arg64Ter)Likely pathogenic
Erythrokeratodermia variabilis et progressiva 4
β˜…β˜†β˜†β˜†2024β†’ Residue 64
NM_002035.4(KDSR):c.413T>G (p.Phe138Cys)Likely pathogenic
not provided
β˜…β˜†β˜†β˜†2024β†’ Residue 138
NM_002035.4(KDSR):c.544G>A (p.Gly182Ser)Likely pathogenic
Erythrokeratodermia variabilis et progressiva 4
β˜…β˜†β˜†β˜†β†’ Residue 182
NM_002035.4(KDSR):c.164_166del (p.Gln55_Gly56delinsArg)Pathogenic
Erythrokeratodermia variabilis et progressiva 4
β˜†β˜†β˜†β˜†2017β†’ Residue 55
NM_002035.4(KDSR):c.256-2A>CPathogenic
Erythrokeratodermia variabilis et progressiva 4
β˜†β˜†β˜†β˜†2017
NM_002035.4(KDSR):c.557A>T (p.Tyr186Phe)Pathogenic
Erythrokeratodermia variabilis et progressiva 4
β˜†β˜†β˜†β˜†2017β†’ Residue 186
View on ClinVar β†—
Related Genes
ASAH2Protein interaction98%DEGS2Protein interaction95%ACER3Protein interaction95%PLPP3Protein interaction95%PLPP2Protein interaction94%SGPP1Protein interaction94%
Tissue Expression6 tissues
Liver
100%
Heart
90%
Brain
78%
Ovary
65%
Lung
52%
Bone Marrow
27%
Gene Interaction Network
Click a node to explore
KDSRASAH2DEGS2ACER3PLPP3PLPP2SGPP1
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted Β· UniProt Q06136
View on AlphaFold β†—
Constraintβ“˜
LOEUFβ“˜
0.96LoF Tolerant
pLIβ“˜
0.04Tolerant
Observed/Expected LoF0.53 [0.31–0.96]
RankingsWhere KDSR stands among ~20K protein-coding genes
  • #8,831of 20,598
    Most Researched50
  • #3,223of 5,498
    Most Pathogenic Variants7
  • #9,134of 17,882
    Most Constrained (LOEUF)0.96
Genes detectedKDSR
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
3-ketodihydrosphingosine reductase mutation induces steatosis and hepatic injury in zebrafish.
PMID: 30718751
Sci Rep Β· 2019
1.00
2
The genetic and molecular basis of a connexin-linked skin disease.
PMID: 39513663
Biochem J Β· 2024
0.90
3
3-Ketodihydrosphingosine reductase maintains ER homeostasis and unfolded protein response in leukemia.
PMID: 34373586
Leukemia Β· 2022
0.80
4
Refractory thrombocytopenia and myelofibrosis in a novel KDSR mutation: Case report and literature review.
PMID: 36546314
Pediatr Blood Cancer Β· 2023
0.70
5
Formation of keto-type ceramides in palmoplantar keratoderma based on biallelic KDSR mutations in patients.
PMID: 34686882
Hum Mol Genet Β· 2022
0.60